Bayer CropScience
BAYERCROP NSE
Bayer CropScience
ChemicalsNSE: BAYERCROP BSE: 506285 Pesticides & Agrochemicals
Key Fundamentals
SmallcapPesticides & AgrochemicalsChemicalsMarket Cap
₹17,838 Cr
Volatility
Moderate
P/E Ratio
24.4
EBITDA
₹969 Cr
Return on Equity
23.24%
Debt to Equity
0.03
Book Value
₹659.9
EPS
₹148.24
52W High
₹5,489
52W Low
₹3,935
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
5- Company has reduced debt.
- Company is almost debt free.
- Stock is providing a good dividend yield of 3.77%.
- Company has been maintaining a healthy dividend payout of 93.8%
- Company's working capital requirements have reduced from 74.0 days to 56.1 days
Weaknesses
1- The company has delivered a poor sales growth of 5.90% over past five years.
Growth Rate
Revenue Growth
3.16% higher than
3Y
Net Income Growth
21.34% higher than
3Y
Cash Flow Change
312% higher than
3Y
ROE
16.61% lower than
3Y
ROCE
16.52% higher than
3Y
EBITDA Margin (Avg.)
16.03% higher than
3Y
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 2d agoAI opinion · based on fundamentals
Risk medium
Bayer CropScience Ltd trades at a market cap of ₹17,838 Cr with a PE of 24.4x and a consistent ROE averaging 23-24% over the last 3-5 years. The company is virtually debt-free and pays a dividend yield of 3.77% with a 93.8% payout ratio, but revenue growth has been sluggish at 3% CAGR over three years and the stock has declined 22% over the past year.
Bull Case 8
- Company is almost debt-free, reducing financial risk and interest burden significantly
- Healthy ROE of 24% in the last year and 23% over 3 years indicates efficient capital allocation and strong profitability
- Dividend yield of 3.77% is well above the broader market average, offering meaningful income to shareholders
- Dividend payout ratio of 93.8% reflects strong commitment to returning cash to shareholders
- TTM profit growth of 24% shows meaningful earnings recovery and margin expansion despite flat revenues
- Working capital days improved from 74.0 days to 56.1 days, indicating better operational efficiency and cash conversion
- 10-year compounded profit growth of 8% and sales growth of 7% demonstrate long-term business resilience
- 5-year ROE of 24% consistently above cost of equity suggests durable competitive advantages in the Indian crop science market
Bear Case 8
- Stock price has declined 22% over the past 1 year, significantly underperforming the broader market
- 3-year stock CAGR of -9% and 5-year CAGR of -6% indicate prolonged value destruction for shareholders
- 10-year stock CAGR of 0% means the stock has generated zero capital appreciation over a decade
- TTM sales growth is -3%, indicating the top line is actually contracting in the most recent period
- 5-year compounded sales growth of only 5.9-6% is weak for a company in the Indian agrochemicals space
- 3-year compounded profit growth of just 1% suggests earnings stagnation over the medium term despite the recent TTM recovery
- PE of 24.4x is not inexpensive given the sluggish revenue growth trajectory and flat long-term stock returns
- A 93.8% dividend payout ratio, while shareholder-friendly, leaves very limited retained earnings for reinvestment and future growth
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 2h ago Positives 1
- ₹60 final dividend declared Aug 19
Shareholders approved a ₹60 per share final dividend at the 68th AGM held on August 19, 2026. Director Jana Marlen Ackermann was also reappointed.
Neutral 2
- New independent director proposed Sep 12
Postal ballot issued on Sep 12 to appoint Ravi Moti Kirpalani as independent director for a five-year term (Sep 1, 2026 – Aug 31, 2031). E-voting runs Sep 14 to Oct 13, 2026.
- Analyst/investor meet scheduled Aug 26
Bayer Crop Science scheduled an analyst and investor meeting for September 2, 2026 at 10:00 am to engage with the investment community.
TL;DR: Bayer CropScience shows steady corporate governance with a healthy ₹60 per share final dividend and routine board-level appointments. No material headwinds have emerged from recent news flow. The analyst meet on Sep 2 could provide forward guidance that moves sentiment, but the current newsflow is largely business-as-usual and mildly positive.
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,740 | 1,617 | 955 | 792 | 1,631 | 1,738 | 1,057 | 1,046 | 1,915 | 1,553 | 1,106 | 1,101 | 1,835 |
| Expenses | 1,315 | 1,312 | 827 | 695 | 1,317 | 1,554 | 1,037 | 876 | 1,566 | 1,348 | 989 | 898 | 1,467 |
| Operating Profit | 425 | 305 | 128 | 97 | 314 | 184 | 20 | 171 | 348 | 205 | 117 | 203 | 368 |
| OPM % | 24% | 19% | 13% | 12% | 19% | 11% | 1.9% | 16% | 18% | 13% | 11% | 18% | 20% |
| Other Income | 21 | 16 | 15 | 29 | 27 | 24 | 32 | 37 | 19 | 14 | 16 | 47 | 89 |
| Interest | 8 | 4 | 3 | 5 | 4 | 3 | 4 | 6 | 5 | 4 | 5 | 6 | 4 |
| Depreciation | 31 | 12 | 15 | 16 | 22 | 14 | 15 | 34 | 27 | 14 | 15 | 38 | 50 |
| PBT | 406 | 306 | 124 | 105 | 316 | 190 | 34 | 168 | 335 | 200 | 113 | 206 | 402 |
| Tax % | 19% | 27% | 25% | 9% | 20% | 28% | -2% | 15% | 17% | 24% | 15% | 21% | 20% |
| Net Profit | 328 | 223 | 93 | 96 | 254 | 136 | 34 | 143 | 279 | 153 | 96 | 162 | 322 |
| EPS in Rs | 73.09 | 49.6 | 20.72 | 21.36 | 56.56 | 30.33 | 7.61 | 31.89 | 62.01 | 33.98 | 21.29 | 36.07 | 71.56 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,660 | 2,769 | 2,803 | 2,710 | 3,167 | 3,609 | 4,261 | 4,734 | 5,140 | 5,106 | 5,473 | 5,675 | 5,595 |
| Expenses | 3,144 | 2,334 | 2,389 | 2,300 | 2,684 | 2,883 | 3,450 | 3,923 | 4,216 | 4,147 | 4,783 | 4,801 | 4,702 |
| Operating Profit | 516 | 435 | 414 | 410 | 483 | 726 | 812 | 812 | 924 | 959 | 691 | 874 | 893 |
| OPM % | 14% | 16% | 15% | 15% | 15% | 20% | 19% | 17% | 18% | 19% | 13% | 15% | 16% |
| Other Income | 88 | 82 | 70 | 39 | 51 | -64 | 69 | 112 | 168 | 76 | 118 | 95 | 165 |
| Interest | 5 | 10 | 7 | 11 | 10 | 14 | 13 | 13 | 22 | 20 | 17 | 20 | 19 |
| Depreciation | 25 | 25 | 29 | 33 | 44 | 65 | 74 | 64 | 80 | 74 | 85 | 94 | 117 |
| PBT | 574 | 482 | 448 | 404 | 480 | 583 | 794 | 847 | 990 | 941 | 707 | 855 | 922 |
| Tax % | 33% | 35% | 35% | 26% | 30% | 19% | 38% | 24% | 23% | 21% | 20% | 19% | — |
| Net Profit | 383 | 315 | 291 | 300 | 337 | 474 | 493 | 645 | 758 | 740 | 568 | 689 | 732 |
| EPS in Rs | 105 | 89.13 | 82.31 | 87.41 | 98.18 | 106 | 110 | 144 | 169 | 165 | 126 | 153 | 163 |
| Div. Payout % | 20% | 19% | 21% | 21% | 18% | 24% | 105% | 104% | 77% | 85% | 99% | 98% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 37 | 35 | 35 | 34 | 34 | 45 | 45 | 45 | 45 | 45 | 45 | 45 |
| Reserves | 1,996 | 1,804 | 2,021 | 1,744 | 2,205 | 2,528 | 2,505 | 2,479 | 2,667 | 2,804 | 2,806 | 2,921 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 2 | 26 | 86 | 74 | 47 | 105 | 82 |
| Other Liabilities | 740 | 597 | 769 | 756 | 1,310 | 1,262 | 1,663 | 1,742 | 1,893 | 1,701 | 2,290 | 2,652 |
| Total Liabilities | 2,773 | 2,437 | 2,825 | 2,535 | 3,549 | 3,836 | 4,239 | 4,353 | 4,679 | 4,597 | 5,246 | 5,699 |
| Fixed Assets | 322 | 290 | 342 | 334 | 440 | 468 | 425 | 468 | 462 | 414 | 470 | 458 |
| CWIP | 1 | 17 | 24 | 36 | 47 | 56 | 76 | 98 | 109 | 119 | 119 | 127 |
| Investments | 29 | 68 | 50 | 0 | 0 | 41 | 52 | 38 | 41 | 54 | 35 | 57 |
| Other Assets | 2,422 | 2,062 | 2,410 | 2,164 | 3,062 | 3,270 | 3,686 | 3,749 | 4,066 | 4,010 | 4,622 | 5,056 |
| Total Assets | 2,773 | 2,437 | 2,825 | 2,535 | 3,549 | 3,836 | 4,239 | 4,353 | 4,679 | 4,597 | 5,246 | 5,699 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 200 | 206 | 157 | 121 | 433 | 666 | 687 | 216 | 609 | 952 | 262 | 1,078 |
| Investing | 485 | 16 | -8 | 38 | -113 | -29 | 7 | 64 | 83 | 0 | 86 | 72 |
| Financing | -42 | -590 | -73 | -581 | -158 | -148 | -556 | -703 | -613 | -656 | -619 | -624 |
| Net Cash Flow | 644 | -367 | 76 | -421 | 162 | 489 | 138 | -424 | 79 | 296 | -272 | 527 |
| Free Cash Flow | 297 | 170 | 108 | 80 | 378 | 638 | 656 | 168 | 537 | 912 | 222 | 1,014 |
| CFO/OP | 76 | 86 | 74 | 53 | 132 | 110 | 105 | 59 | 92 | 113 | 61 | 142 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 57 | 53 | 72 | 89 | 81 | 73 | 65 | 77 | 69 | 69 | 63 | 72 |
| Inventory Days | 85 | 169 | 178 | 175 | 294 | 206 | 226 | 235 | 268 | 222 | 319 | 289 |
| Days Payable | 40 | 52 | 67 | 67 | 164 | 101 | 142 | 127 | 129 | 87 | 148 | 167 |
| Cash Conversion Cycle | 102 | 171 | 184 | 197 | 211 | 177 | 149 | 185 | 208 | 204 | 234 | 193 |
| Working Capital Days | 53 | 92 | 104 | 134 | 116 | 77 | 61 | 84 | 86 | 78 | 88 | 56 |
| ROCE % | 31% | 25% | 23% | 22% | 25% | 30% | 31% | 31% | 34% | 34% | 25% | 29% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Bayer CropScience insights
62 extracted metrics + investor summaries across FY11–FY26.
Documents
1
Announcement under Regulation 30 (LODR)-Newspaper Publication
12 Sep - Pursuant to Regulation 30 and 47 read with Schedule III Part A Para A of SEBI (LODR) Regulations, 2015 we hereby enclose copies of newspaper … 12 Sep - Pursuant to Regulation 30 and 47 read with Schedule III Part A Para A of SEBI (LODR) Regulations, 2015 we hereby enclose copies of newspaper …
3
Board Meeting Intimation for The Quarter And Financial Year Ended March 31, 2026.
10h - Board meets May 26, 2026 for audited FY26 results and possible final dividend. 10h - Board meets May 26, 2026 for audited FY26 results and possible final dividend.
4
Announcement under Regulation 30 (LODR)-Newspaper Publication
5 May - Read with Schedule III Part A Para A of SEBI LODR Regulations, 2015, we hereby enclose newspaper advertisements published in Financial Express and Loksatta on … 5 May - Read with Schedule III Part A Para A of SEBI LODR Regulations, 2015, we hereby enclose newspaper advertisements published in Financial Express and Loksatta on …
5
Announcement under Regulation 30 (LODR)-Newspaper Publication
28 Apr - Copies of newspaper advertisement regarding relaunch of 100 days Campaign by IEPF. This is for your information and record. 28 Apr - Copies of newspaper advertisement regarding relaunch of 100 days Campaign by IEPF. This is for your information and record.
3
Announcement Under Regulation 30 Regarding ESG Rating By Crisil ESG Ratings And Analytics Limited 1 Sept 2026
General_Announcements
Frequently Asked Questions about Bayer CropScience
What does Bayer CropScience Ltd do?
Bayer CropScience is engaged in Agri Care business which primarily includes manufacture, sale and distribution of insecticides, fungicides, herbicide and various other agrochemical products and corn seeds.[1]
Where is Bayer CropScience Ltd (BAYERCROP) listed?
Bayer CropScience Ltd trades as BAYERCROP on the NSE and under code 506285 on the BSE.
Which sector does Bayer CropScience Ltd belong to?
Bayer CropScience Ltd is classified under the Chemicals sector, in the Pesticides & Agrochemicals industry.
What is the market capitalisation of Bayer CropScience Ltd?
Bayer CropScience Ltd has a market capitalisation of ₹17,838 Cr, which places it in the Mid Cap band.
What is the PE ratio of Bayer CropScience Ltd?
Bayer CropScience Ltd trades at a PE ratio of 24.40, on earnings per share of ₹148.24, against a book value of ₹659.9 per share.
What is the 52-week high and low of Bayer CropScience Ltd?
Over the last 52 weeks Bayer CropScience Ltd has traded between ₹3,935 and ₹5,489.
Does Bayer CropScience Ltd pay dividends?
Bayer CropScience Ltd has a dividend yield of 3.77%.
What is the Return on Equity (ROE) of Bayer CropScience Ltd?
Bayer CropScience Ltd reported a return on equity of 23.24%. Its debt-to-equity ratio is 0.03.
Company Information
Bayer CropScience is engaged in Agri Care business which primarily includes manufacture, sale and distribution of insecticides, fungicides, herbicide and various other agrochemical products and corn seeds.[1]
Website bayer.in
CEO Mr. Simon-Thorsten Wiebusch
Employees 1,169
Listed 2010-01-08
Face Value ₹ 10
Issued Size 5,01,07,246
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/BAYERCROP.md for Bayer CropScience Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.